Given the promising use of anti‐IL‐1 drugs in other well‐known autoinflammatory disorders107 as well as the role of this alarmin in promoting immunotherapy resistance in melanoma, alongside its plausible clinical use as a predictive marker of immunotherapy response, a novel therapeutic choice in cutaneous melanoma could result from the use of anti‐IL‐1 drugs in combination with immunotherapy. Here, IL1B is linked to cutaneous melanoma.